Assessment of the presence and anti-tumor potential of tumor-infiltrating lymphocytes in patients with acute myeloid leukemia

References

• Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 2008;19(4):379–390. doi:10.1007/s10552-007-9097-218064533
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.2129425559415
   PubMed Web of Science ®Google Scholar
• D€Ohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra140618426376137
   PubMed Web of Science ®Google Scholar
• Shah A, Andersson TM, Rachet B, Bjorkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971–2006: a population-based study. Br J Haematol. 2013;162(4):509–516. doi:10.1111/bjh.1242523786647
   PubMed Web of Science ®Google Scholar
• Meyers J, Yu Y, Kaye JA, Davis KL. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11(3):275–286. doi:10.1007/s40258-013-0032-223677706
   PubMedGoogle Scholar
• Kantarjian H, O’Brien S. Questions regarding frontline therapy of acute myeloid leukemia. Cancer. 2010;116(21):4896–4901. doi:10.1002/cncr.2528120623787
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51(6):786–792. doi:10.1038/bmt.2016.2026901709
   PubMed Web of Science ®Google Scholar
• Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time dependent analysis. Lancet Haematol. 2015;2(10):e427–436. doi:10.1016/S2352-3026(15)00148-926686044
   PubMed Web of Science ®Google Scholar
• Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths,controversies, and unknowns. Blood. 2011;117(8):2307–2318. doi:10.1182/blood-2010-10-26560321098397
   PubMed Web of Science ®Google Scholar
• Duval M, Klein JP, He W, Cahn JY. Cairo: hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730–3738. doi:10.1200/JCO.2010.28.885220625136
   PubMed Web of Science ®Google Scholar
• Lichtenegger FS, Schnorfeil FM, Hiddemann W, Subklewe M. Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy. 2013;5(1):63–78. doi:10.2217/imt.12.14523256799
   PubMed Web of Science ®Google Scholar
• Lichtenegger FS, Krupka C, Köhnke T, Subklewe M. Immunotherapy for acute myeloid leukemia. Semin Hematol. 2015;52(3):207–214. doi:10.1053/j.seminhematol.2015.03.00626111468
   PubMed Web of Science ®Google Scholar
• Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European leukemianet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579–590. doi:10.1038/nrclinonc.2012.15422949046
   PubMed Web of Science ®Google Scholar
• Stelljes M, Krug U, Beelen DW, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol. 2014;32(4):288–296. doi:10.1200/JCO.2013.54.691124366930
   PubMed Web of Science ®Google Scholar
• Ramos NR, Mo CC, Karp JE, Hourigan CS. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665–695. doi:10.3390/jcm404066525932335
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer Genome Landscapes. Science. 2013;339(6127):1546–1558. doi:10.1126/science.123512223539594
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218. doi:10.1038/nature1221323770567
   PubMed Web of Science ®Google Scholar
• Lu YC, Yao X, Crystal JS, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014;20(13):340–3410. doi:10.1158/1078-0432.CCR-13-3045
   Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–752. doi:10.1038/nm.316123644516
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–4557. doi:10.1158/1078-0432.CCR-11-011621498393
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013;19(17):4792–4800. doi:10.1158/1078-0432.CCR-13-038023690483
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–854. doi:10.1126/science.107651412242449
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. doi:10.1126/science.aaa513925838374
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–645. doi:10.1126/science.125110224812403
   PubMed Web of Science ®Google Scholar
• Kahl C, Krahl R, Becker C, et al. Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German haematology and oncology study group (OSHO). J Cancer Res Clin Oncol. 2016;142(1):305–315. doi:10.1007/s00432-016-2126-326407768
   PubMed Web of Science ®Google Scholar
• Champlin R. Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol. 2013;26(3):297–300. doi:10.1016/j.beha.2013.10.01124309534
   PubMed Web of Science ®Google Scholar
• Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017–4023. doi:10.1182/blood-2014-07-59104025999455
   PubMed Web of Science ®Google Scholar
• Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol Res. 2016;4(3):204–214. doi:10.1158/2326-6066.CIR-15-018826701267
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Gartner JJ, Horovitz-Fried M, et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 2015;125(10):3981–3991. doi:10.1172/JCI8032326389673
   PubMed Web of Science ®Google Scholar
• Ye Q, Song DG, Poussin M, et al. CD137 accurately identifies and enriches for naturally-occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20(1):44–55. doi:10.1158/1078-0432.CCR-13-304524045181
   PubMed Web of Science ®Google Scholar
• Ben‑Avi R, Farhi R, Ben-Nun A, et al. Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother. 2018;67(8):1221–1230. doi:10.1007/s00262-018-2174-429845338
   PubMed Web of Science ®Google Scholar
• Hall M, Liu H, Malafa M, et al. Expansion of tumor-infiltrating lymphocytes(TIL) from human pancreatic tumors. J Immunother Cancer. 2016;4:61. doi:10.1186/s40425-016-0164-727777771
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213. doi:10.1056/NEJMoa02017712529460
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Sedgwick CG, Shahid A, et al. Toward personalized lymphoma immunotherapy identification of common driver mutations recognized by patient CD8+ T cells. Clin Cancer Res. 2016;22(9):2226–2236. doi:10.1158/1078-0432.CCR-15-202326631611
   PubMed Web of Science ®Google Scholar
• Linnemann C, van Buuren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015;21(1):81–85. doi:10.1038/nm.377325531942
   PubMed Web of Science ®Google Scholar
• Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus–targeted tumor-infiltrating T cells. J Clin Oncol. 2015;33(14):1543–1550. doi:10.1200/JCO.2014.58.909325823737
   PubMed Web of Science ®Google Scholar
• Assadipour Y, Zacharakis N, Crystal JS, et al. Characterization of an immunogenic mutation in a patient with metastatic triple negative breast cancer. Clin Cancer Res. 2017;23(15):4347–4353. doi:10.1158/1078-0432.CCR-16-142328377481
   PubMed Web of Science ®Google Scholar
• Inozume T, Hanada K, Wang QJ, et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010;33(9):956–964. doi:10.1097/CJI.0b013e3181fad2b020948441
   PubMed Web of Science ®Google Scholar
• Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23–68. doi:10.1146/annurev.immunol.23.021704.11583915771565
   PubMed Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433–438. doi:10.1038/nm.405126901407
   PubMed Web of Science ®Google Scholar